当前位置:首页 - 行情中心 - 柳药集团(603368) - 财务分析 - 利润表

柳药集团

(603368)

  

流通市值:70.54亿  总市值:70.84亿
流通股本:3.97亿   总股本:3.99亿

利润表

报告期2024-12-312024-09-302024-06-302024-03-31
公司类型通用通用通用通用
一、营业总收入21,182,454,178.2615,992,976,622.1910,641,992,346.595,774,668,302.52
营业收入21,182,454,178.2615,992,976,622.1910,641,992,346.595,774,668,302.52
二、营业总成本20,166,805,761.415,081,535,497.5210,030,636,921.15,376,679,255.82
营业成本18,774,823,172.6114,111,707,954.789,385,063,709.775,067,179,156.36
税金及附加63,599,669.9441,658,315.7728,748,300.3813,940,270.8
销售费用629,684,429.75430,997,572.17285,325,562.89134,942,515.39
管理费用423,863,503.09299,281,950.74195,156,038.8899,266,922.64
研发费用39,629,592.2921,663,634.2414,008,342.086,819,252.74
财务费用235,205,393.72176,226,069.82122,334,967.154,531,137.89
其中:利息费用214,545,031.94163,986,547.99109,845,297.9174,129,214.45
其中:利息收入36,925,040.3729,857,128.6818,803,406.611,976,295.4
加:投资收益-95,285.99-10,900.22-45,066.81-11,462.55
资产处置收益3,025,141.41599,416.36735,970.29-
信用减值损失(新)-32,119,064.88-70,143,170.84-55,063,393.33-40,343,781.14
其他收益17,138,770.5212,994,850.476,926,708.262,434,395.02
营业利润平衡项目0000
四、营业利润1,003,597,977.92854,881,320.44563,909,643.9360,068,198.03
加:营业外收入14,587,726.064,432,545.672,900,167.012,426,434.74
减:营业外支出15,049,521.142,639,776.071,755,296.2928,909.73
利润总额平衡项目0000
五、利润总额1,003,136,182.84856,674,090.04565,054,514.71361,565,723.04
减:所得税费用135,601,795.28111,135,446.9374,281,157.5348,767,448.69
六、净利润867,534,387.56745,538,643.11490,773,357.18312,798,274.35
持续经营净利润867,534,387.56745,538,643.11490,773,357.18312,798,274.35
归属于母公司股东的净利润854,872,384715,908,021.45464,193,662.02300,349,057.76
少数股东损益12,662,003.5629,630,621.6626,579,695.1612,449,216.59
(一)基本每股收益2.211.871.240.83
(二)稀释每股收益2.211.871.240.83
九、综合收益总额867,534,387.56745,538,643.11490,773,357.18312,798,274.35
归属于母公司股东的综合收益总额854,872,384715,908,021.45464,193,662.02300,349,057.76
归属于少数股东的综合收益总额12,662,003.5629,630,621.6626,579,695.1612,449,216.59
公告日期2025-03-272024-10-302024-08-292024-04-26
审计意见(境内)标准无保留意见
TOP↑